Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers
Phase 2
Completed
- Conditions
- Acute Bacterial Corneal UlcersBacterial Keratitis
- Interventions
- Registration Number
- NCT00651586
- Lead Sponsor
- Allergan
- Brief Summary
This study evaluates the safety and efficacy of gatifloxacin 0.3% ophthalmic solution compared with ciprofloxacin 0.3% ophthalmic solution in patients with acute bacterial corneal ulcers
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 129
Inclusion Criteria
- Clinical diagnosis in one eye only of an acute bacterial corneal ulcer (>1mm)
Exclusion Criteria
- Corneal ulcer that in the opinion of the investigator had to be treated with fortified antibiotics, or multiple antibiotics, or anti-infectives other than study medication
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Ciprofloxacin 0.3% ophthalmic solution Ciprofloxacin 0.3% ophthalmic solution 1 Gatifloxacin 0.3% ophthalmic solution Gatifloxacin 0.3% ophthalmic solution
- Primary Outcome Measures
Name Time Method Complete re-epithelialization of the corneal ulcer Day 21
- Secondary Outcome Measures
Name Time Method Microbiological Cure Day 21 Patient reported outcomes Day 21 Investigator's evaluation of clinical efficacy Day 21
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie gatifloxacin's efficacy in treating acute bacterial corneal ulcers compared to ciprofloxacin?
How does the fluoroquinolone class of antibiotics, including gatifloxacin and ciprofloxacin, target bacterial DNA gyrase and topoisomerase IV in corneal ulcer treatment?
What biomarkers are associated with improved outcomes in bacterial keratitis patients treated with 0.3% ophthalmic fluoroquinolones?
What are the comparative adverse event profiles of gatifloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in ocular infections?
How do gatifloxacin and ciprofloxacin compare to newer fluoroquinolones like moxifloxacin in treating Pseudomonas aeruginosa corneal ulcers?